155 related articles for article (PubMed ID: 18847314)
1. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.
Ding C
Expert Opin Biol Ther; 2008 Nov; 8(11):1805-14. PubMed ID: 18847314
[TBL] [Abstract][Full Text] [Related]
2. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
3. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
Jin X; Ding C
Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
[TBL] [Abstract][Full Text] [Related]
4. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
5. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
[TBL] [Abstract][Full Text] [Related]
6. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
7. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
8. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
9. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
10. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
11. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B.
Drugs R D; 2010; 10(1):55-65. PubMed ID: 20509716
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
13. Targeting BLyS in systemic lupus erythematosus.
Liu Y; La Cava A
Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):91-6. PubMed ID: 22216778
[TBL] [Abstract][Full Text] [Related]
14. Belimumab therapy in systemic lupus erythematosus.
Zouali M; Uy EA
BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
[TBL] [Abstract][Full Text] [Related]
15. Anticytokine therapy impacting on B cells in autoimmune diseases.
Daridon C; Burmester GR; Dörner T
Curr Opin Rheumatol; 2009 May; 21(3):205-10. PubMed ID: 19346949
[TBL] [Abstract][Full Text] [Related]
16. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
Halpern WG; Lappin P; Zanardi T; Cai W; Corcoran M; Zhong J; Baker KP
Toxicol Sci; 2006 Jun; 91(2):586-99. PubMed ID: 16517838
[TBL] [Abstract][Full Text] [Related]
18. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Samy E; Wax S; Huard B; Hess H; Schneider P
Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
[TBL] [Abstract][Full Text] [Related]
19. Belimumab: a guide to its use in systemic lupus erythematosus.
Scott LJ; Burness CB; McCormack PL
BioDrugs; 2012 Jun; 26(3):195-9. PubMed ID: 22428610
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
